Overall market sentiment has been down on Mirum Pharmaceuticals Inc (MIRM) stock lately. MIRM receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Mirum Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on MIRM!
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With MIRM Stock Today?
Mirum Pharmaceuticals Inc (MIRM) stock is trading at $31.99 as of 11:59 AM on Wednesday, Nov 29, a rise of $0.66, or 2.09% from the previous closing price of $31.33. The stock has traded between $31.45 and $32.48 so far today. Volume today is light. So far 150,305 shares have traded compared to average volume of 486,061 shares.
To see InvestorsObserver's Sentiment Score for Mirum Pharmaceuticals Inc click here.
More About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Click Here to get the full Stock Report for Mirum Pharmaceuticals Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
